Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Direxion Daily S&P 500 Bull 3X Shares trades at $268.38. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | SPXL | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $288.04 |
52-Week Low | $20.06 | $170.20 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SPXL, a leveraged ETF tracking the S&P 500, trades at $275.77, up 2.62% with strong bullish technical signals from moving averages. Recent sector rotation has pressured tech stocks, though broader market optimism persists. The fund's performance is tied to daily S&P 500 returns, with a dividend scheduled for June 2026.
Outlook remains tied to S&P 500 momentum, with potential for gains if earnings meet high expectations, but risks include volatility decay from daily rebalancing and market corrections. Investors should weigh the ETF's leverage against broader economic indicators and sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
